Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy

NCT02983799 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02983799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02983799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 22, 2016
Completion date
December 3, 2020
Enrollment
272 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed ovarian cancer, brca mutation, platinum sensitivity